Interferon alpha and antisense K-ras RNA combination gene therapy
View Patent ↗Methods of suppressing growth of pancreatic tumors or cancer cells having a K-ras gene point mutation in a mammal, comprising: administering therapeutically effective amounts of adenoviral vector and antisense K-ras expressing vector to pancreatic cancer cells via intratumoral administration, wherein the adenoviral vector comprises a DNA sequence encoding a human IFN-alpha and operably linked to a promoter, and the pancreatic cancer cells to which the adenoviral vector is administered express the human IFN-alpha; and the antisense K-ras expressing vector comprises an antisense K-ras nucleotide sequence, wherein the antisense K-ras nucleotide sequence is operably linked to a promoter, and the pancreatic cancer cells to which the anti-sense K-ras expressing vector is administered express the antisense K-ras nucleotide sequence; whereby expression of the human IFN-alpha and the antisense K-ras nucleotide sequence suppress growth of pancreatic tumor or cancer cells in the mammal.
1. A method of suppressing growth of pancreatic tumors or cancer cells having a K-ras gene point mutation in a mammal, comprising: administering therapeutically effective amounts of adenoviral vector and antisense K-ras expressing vector to pancreatic cancer cells of the mammal via intratumoral administration, wherein the adenoviral vector comprises a DNA sequence encoding human IFN-alpha and operably linked to a promoter, wherein the pancreatic cancer cells to which the adenoviral vector is administered express the human IFN-alpha; and the antisense K-ras expressing vector comprises an antisense K-ras nucleotide sequence operably linked to a promoter, wherein the pancreatic cancer cells to which the anti-sense K-ras expressing vector is administered express the antisense K-ras nucleotide sequence; whereby expression of the human IFN-alpha and the antisense K-ras nucleotide sequence suppresses growth of pancreatic tumor or cancer cells in the mammal.
2. The method of claim 1 , wherein the promoter of the adenoviral vector is a beta-actin promoter fused to a cytomegalovirus enhancer element.
3. The method of claim 1 , wherein the promoter of the antisense K-ras expressing vector is a beta-actin promoter fused to a cytomegalovirus enhancer element.
4. The method of claim 1 , wherein the adenoviral vector is administered in a dose ranging from about 5×10 8 to 25×10 8 pfu (plaque forming unit)/day/tumor weight (g).
5. The method of claim 1 , wherein the antisense K-ras expressing vector is administered in a dose ranging from about 5×10 8 to 25×10 8 pfu (plaque forming unit)/day/tumor weight (g).
6. The method of claim 1 , comprising administering both vectors to pancreatic cancer cells at the pancreas, administering both vectors to pancreatic cancer cells not localized at the pancreas, or a combination thereof.
7. The method of claim 1 , comprising administering both vectors to pancreatic cancer cells at the pancreas, and causing regression of pancreatic cancer cells at the pancreas or regression of pancreatic cancer cells anywhere in the mammal.
8. The method of claim 1 , comprising administering both vectors to pancreatic cancer cells localized distant from the pancreas, and causing regression of pancreatic cancer cells at the pancreas or pancreatic cancer cells anywhere in the mammal.
9. The method of claim 1 , wherein the vectors are administered to an identifiable mass of pancreatic cancer cells not localized at the pancreas.
10. The method of claim 1 , wherein an antitumor effect is observed systemically.
11. A method of inducing apoptosis in pancreatic cancer cells having a K-ras gene point mutation in a mammal comprising administering to the mammal via intratumoral administration at least one combination using two or more components with at least one component being a vector comprising a DNA sequence encoding interferon-alpha and at least one component being a vector comprising an antisense K-ras RNA nucleotide sequence.